Spectrum Electrical Industries Ltd approves Q2 & H1 results for period ended September 30, 2026
Spectrum Electrical Industries · Industrial Manufacturing
Key highlights
- Board approved standalone and consolidated unaudited results for quarter and half year ended September 30, 2026 on November 7, 2026
- Half year ended September 30, 2026 profit before tax: Rs. 4,706.88 Lakhs consolidated and Rs. 4,732.22 Lakhs standalone
- CRISIL Ratings Limited monitoring agency report and statement of deviation confirm no deviation in utilisation of preferential issue funds
Why it's rated major development: the year-on-year change is 132% (50% or more)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Submission Of Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026, Pursuant To Regulation 33 Of SEBI (LODR) Regulations, 2015.
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Spectrum Electrical Industries
- Fundraise / allotmentNotableSpectrum Electrical Industries lists 13,73,625 preferential equity shares on NSE and BSE
- Fundraise / allotmentNotableSpectrum Electrical Industries gets NSE and BSE approval for listing 13,73,625 equity shares
Other financial results filings this fortnight
- Siddhika Coatings Limited approves joint venture and announces H1 FY 2026 financials
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2026 unaudited financial results
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2027 financial results and divestment
- NHC Foods reports Sept 2026 quarter results, 99.98% firm stake, two appointments
- Dev Labtech Venture reports unaudited half-year results to 30 Sept 2026
- Kilitch Drugs (India) approves unaudited Q2 and half-year results to 30 Sept 2026
Potential multibaggers · Q2 FY27
Potential multibaggers in Industrial Manufacturing
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.